In preclinical models, the Sofusa^™ platform has demonstrated potential across a wide range of diseases by successfully delivering both small and large molecules without reformulation.

The Sofusa^™ platform has demonstrated the ability to deliver drugs transdermally across a wide range of molecule sizes, volumes and viscosities.

The core Sofusa^™ platform technology has been integrated into different device designs tailored to meet the needs of patients across various disease areas, from acute migraine, to rheumatoid arthritis, to cancer.